Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.
Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.
Multigene panel testing can identify mutations that warrant management changes in patients who lack BRCA1 and 2.
A prescription drug’s label AE section is almost entirely based on clinicians’ impression of patients’ symptoms, not the patients’ own reports.
The incidence of endometrial cancers is elevated for women across all racial/ethnic groups, while non-Hispanic black women have excess incidence.
Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC).
Multigene testing for hereditary breast and/or ovarian cancer (HBOC) identifies more mutations that are likely to change clinical management.
RAD51C and RAD51D are moderate ovarian cancer susceptibility genes.
About thirty percent of women with epithelial ovarian cancer survive for more than 10 years, including some with high-risk disease.
The use of botulinum toxin to treat painful cutaneous leiomyomas was associated with improved quality of life.
Use of oral contraceptives confers long-term protection against endometrial cancer.